Skye Bioscience (SKYE) Competitors $3.21 -0.54 (-14.40%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$3.26 +0.06 (+1.71%) As of 01/31/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SKYE vs. VYGR, TRVI, ENGN, SOPH, ATYR, DSGN, IMMP, ELDN, CTNM, and YMABShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Voyager Therapeutics (VYGR), Trevi Therapeutics (TRVI), enGene (ENGN), SOPHiA GENETICS (SOPH), Atyr PHARMA (ATYR), Design Therapeutics (DSGN), Immutep (IMMP), Eledon Pharmaceuticals (ELDN), Contineum Therapeutics (CTNM), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Voyager Therapeutics Trevi Therapeutics enGene SOPHiA GENETICS Atyr PHARMA Design Therapeutics Immutep Eledon Pharmaceuticals Contineum Therapeutics Y-mAbs Therapeutics Skye Bioscience (NASDAQ:SKYE) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment. Do analysts prefer SKYE or VYGR? Skye Bioscience currently has a consensus target price of $18.67, suggesting a potential upside of 481.52%. Voyager Therapeutics has a consensus target price of $15.97, suggesting a potential upside of 192.96%. Given Skye Bioscience's higher probable upside, equities analysts plainly believe Skye Bioscience is more favorable than Voyager Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the MarketBeat Community believe in SKYE or VYGR? Voyager Therapeutics received 383 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 67.70% of users gave Voyager Therapeutics an outperform vote. CompanyUnderperformOutperformSkye BioscienceOutperform Votes11100.00% Underperform VotesNo VotesVoyager TherapeuticsOutperform Votes39467.70% Underperform Votes18832.30% Is SKYE or VYGR more profitable? Voyager Therapeutics has a net margin of 15.80% compared to Skye Bioscience's net margin of 0.00%. Voyager Therapeutics' return on equity of 8.33% beat Skye Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -45.78% -37.44% Voyager Therapeutics 15.80%8.33%6.15% Which has stronger valuation and earnings, SKYE or VYGR? Voyager Therapeutics has higher revenue and earnings than Skye Bioscience. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$37.65MN/AN/AVoyager Therapeutics$250.01M1.19$132.33M$0.717.68 Do institutionals & insiders have more ownership in SKYE or VYGR? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are held by institutional investors. 3.0% of Skye Bioscience shares are held by company insiders. Comparatively, 4.5% of Voyager Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer SKYE or VYGR? In the previous week, Voyager Therapeutics had 7 more articles in the media than Skye Bioscience. MarketBeat recorded 9 mentions for Voyager Therapeutics and 2 mentions for Skye Bioscience. Skye Bioscience's average media sentiment score of 1.00 beat Voyager Therapeutics' score of 0.67 indicating that Skye Bioscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, SKYE or VYGR? Skye Bioscience has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. SummaryVoyager Therapeutics beats Skye Bioscience on 12 of the 16 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BiosciencePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.39M$6.87B$5.57B$9.12BDividend YieldN/A2.90%5.31%3.98%P/E RatioN/A9.9789.9118.25Price / SalesN/A319.181,257.0888.31Price / CashN/A73.5045.9637.70Price / Book-18.885.275.124.71Net Income-$37.65M$136.98M$111.09M$224.24M7 Day Performance15.30%-0.75%0.09%-0.25%1 Month Performance13.43%0.05%3.20%1.48%1 Year Performance-19.75%8.98%25.75%21.06% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience1.4478 of 5 stars$3.21-14.4%$18.67+481.5%-19.3%$104.06MN/A0.0011News CoveragePositive NewsGap UpHigh Trading VolumeVYGRVoyager Therapeutics4.7456 of 5 stars$5.63+0.1%$15.97+183.8%-25.0%$307.35M$250.01M7.92100TRVITrevi Therapeutics2.5838 of 5 stars$3.97+1.5%$9.31+134.7%+177.5%$304.94MN/A-9.0220Short Interest ↓News CoverageENGNenGene3.052 of 5 stars$6.80-5.1%$29.78+338.2%-14.5%$300.48MN/A-11.7231Short Interest ↓News CoverageSOPHSOPHiA GENETICS2.8195 of 5 stars$4.46+6.1%$7.40+66.1%-23.7%$291.31M$64.49M-4.09520Short Interest ↓Gap DownHigh Trading VolumeATYRAtyr PHARMA2.4713 of 5 stars$3.47-3.5%$19.25+455.6%N/A$290.85M$350,000.00-3.6953Short Interest ↑News CoveragePositive NewsDSGNDesign Therapeutics2.1546 of 5 stars$5.05+1.5%$7.00+38.8%+104.6%$285.65MN/A-5.9440Short Interest ↑News CoverageGap DownIMMPImmutep1.8904 of 5 stars$1.94-1.5%$8.50+339.3%-3.7%$281.66M$5.14M0.002,021News CoverageELDNEledon Pharmaceuticals3.094 of 5 stars$4.67+5.3%$16.00+243.0%+153.9%$278.69MN/A-2.3210Analyst ForecastShort Interest ↓CTNMContineum Therapeutics3.2561 of 5 stars$10.79-3.5%$29.25+171.2%N/A$278.06M$50M0.0031Upcoming EarningsGap DownYMABY-mAbs Therapeutics2.1259 of 5 stars$6.20-0.9%$20.89+237.2%-53.3%$277.47M$84.82M-11.47150 Related Companies and Tools Related Companies VYGR Alternatives TRVI Alternatives ENGN Alternatives SOPH Alternatives ATYR Alternatives DSGN Alternatives IMMP Alternatives ELDN Alternatives CTNM Alternatives YMAB Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SKYE) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
